DataMEDS AI launches new corporate website after acquisition and settlement

DataMEDS AI has launched a new corporate website as it resets its branding and marketing following the acquisition of Helomics’ AI cancer diagnostics lab and a litigation settlement that removed about $19 million in liabilities. The company says the move sets up an upcoming soft launch of its Health Lives Here consumer app.

Why it matters: - DataMEDS AI is trying to reposition itself around artificial intelligence, consumer health apps and broader market visibility. - The website launch follows a balance-sheet cleanup and a lab acquisition that could shape the company’s next phase. - The company says it is preparing to soft launch its Health Lives Here app in short order.

What happened: - DataMEDS AI launched its new corporate website, www.DataMedsAI.com, on Sept. 21, 2026. - The new site is part of the company’s updated branding after recent corporate changes. - Interim Co-CEO Gerald E. Commissiong said the company is now poised to launch the Health Lives Here consumer application and begin telling the DataMEDS story to a broader market. - DataMEDS AI says it has retooled its marketing to be AI-centric and aims to generate organic traffic and earned media interest.

The details: - DataMEDS AI recently announced the acquisition of Helomics Corporation’s artificial intelligence cancer diagnostics lab from Axe Compute. - The company also settled outstanding litigation tied to the May 11, 2023 acquisition of Wellgistics, LLC. - The settlement extinguished about $19 million in liabilities from the balance sheet and retired 364,099 common shares. - DataMEDS AI is a Health IT company focused on vertically integrating health data acquisition and transfer. - The company is headquartered in Tampa, Fla., and trades on Nasdaq under the ticker MEDS. - DataMEDS AI says its Health Lives Here mobile application incorporates the EinsteinRx AI platform and the blockchain-enabled PharmacyChain platform. - The company’s Corexa Health subsidiary provides pharmacy and pharmacy services, including distribution of products developed by Tollo Health, LLC. - DataMEDS AI is a B2i Digital Featured Company, with an in-depth profile available here.

Between the lines: - The website launch is not just a branding exercise; it signals a broader effort to connect the company’s acquisition strategy, technology stack and consumer-facing products into one story. - The settlement and debt reduction give DataMEDS AI a cleaner financial backdrop as it pushes into new initiatives. - The company’s forward-looking language suggests management wants investors to focus on platform expansion, but those plans remain contingent on execution and approvals.

What's next: - DataMEDS AI expects to soft launch the Health Lives Here app soon. - The company says it plans to keep expanding into telemedicine and diagnostic laboratory services. - DataMEDS AI also says it is pursuing a proposed transaction with DataVault AI Inc., Scilex Holding Company, EOS Holdings and HealthBridge Advisors, subject to closing conditions and approvals.